Role of heart rate as a marker and mediator of poor outcome for patients with heart failure

被引:16
作者
John R. Kapoor
Paul A. Heidenreich
机构
[1] University of Chicago Pritzker, School of Medicine, Chicago, IL 60031
[2] Veterans Affairs Palo Alto Health Care System, Palo Alto, CA
关键词
Beta-blockers; Heart failure; Heart rate; Hospitalization; Ivabradine; Management; Mortality; Pharmaceuticals; Pharmacotherapy; Risk factors; Tachycardia;
D O I
10.1007/s11897-012-0086-8
中图分类号
学科分类号
摘要
Tachycardia has been associated with worse outcomes for patients with heart failure and is also thought to have a direct adverse impact on the myocardium. This report highlights the current evidence for heart rate as both a risk factor and mediator for poor outcome for patients with heart failure. We summarize the large number of studies evaluating heart rate in patients with systolic dysfunction and newer studies that examine patients with preserved systolic function. The effect on outcomes in heart failure of medications known to slow the heart rate such as β-blockers and the more recently developed drug ivabradine are discussed. The data clearly show that a high heart rate is a marker of increased mortality. There is also a strong suggestion that a higher heart rate directly worsens outcome and that this can be mitigated by heart rate-reducing medications. © 2012 Springer Science+Business Media, LLC.
引用
收藏
页码:133 / 138
页数:5
相关论文
共 55 条
[1]  
Palatini P., Casiglia E., Julius S., Pessina A.C., High heart rate: A risk factor for cardiovascular death in elderly men, Archives of Internal Medicine, 159, 6, pp. 585-592, (1999)
[2]  
Kannel W.B., Kannel C., Paffenbarger Jr. R.S., Cupples A., Heart rate and cardiovascular mortality: The Framingham study, American Heart Journal, 113, 6, pp. 1489-1494, (1987)
[3]  
Fox K., Ford I., Steg P.G., Et al., Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial, Lancet, 372, pp. 807-816, (2008)
[4]  
Swedberg K., Komajda M., Bohm M., Et al., Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebocontrolled study, Lancet, 376, pp. 875-885, (2010)
[5]  
Shinbane J.S., Wood M.A., Jensen D.N., Ellenbogen K.A., Fitzpatrick A.P., Scheinman M.M., Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies, Journal of the American College of Cardiology, 29, 4, pp. 709-715, (1997)
[6]  
Moe G.W., Armstrong P., Pacing-induced heart failure: A model to study the mechanism of disease progression and novel therapy in heart failure, Cardiovascular Research, 42, 3, pp. 591-599, (1999)
[7]  
Yarbrough W.M., Spinale F.G., Large animal models of congestive heart failure: A critical step in translating basic observations into clinical applications, Journal of Nuclear Cardiology, 10, 1, pp. 77-86, (2003)
[8]  
Nagatsu M., Spinale F.G., Koide M., Tagawa H., DeFreitas G., Cooper IV G., Carabello B.A., Bradycardia and the role of β-blockade in the amelioration of left ventricular dysfunction, Circulation, 101, 6, pp. 653-659, (2000)
[9]  
Schulz R., Aker S., Belosjorow S., Konietzka I., Rauen U., Heusch G., Stress kinase phosphorylation is increased in pacing-induced heart failure in rabbits, American Journal of Physiology - Heart and Circulatory Physiology, 285, 5, (2003)
[10]  
Heusch P., Canton M., Aker S., Et al., The contribution of reactive oxygen species and p38 mitogen activated protein kinase to myofilament oxidation and progression of heart failure in rabbits, Br J Pharmacol, 160, pp. 1408-1416, (2010)